Hutchison, James C.; Wilkinson, William H.; Lintgen, Arthur B.
December 1971
Angiology;Dec1971, Vol. 22 Issue 11, p647
Academic Journal
In an open, crossover study of six months' duration, clonidine given alone and with chlorthalidone was compared in 37 patients completing the study. Significant blood pressure lowering was achieved following both clonidine and clonidine with chlorthalidone. The response was highly significant following the combination. While there was a systolic orthostatic effect, tolerance developed only after clonidine alone in this study. Adverse effects were frequently reported. They were an annoying feature of the drug, but no major toxic effects were seen, and the only significant laboratory abnormalities were those associated with diuretic therapy. Bradycardia was a common finding. Based on the findings of this study, clonidine is a valuable additional tool for the management of hypertensive vascular disease. The combination with chlorthalidone provides a much more predictable means of controlling blood pressure than clonidine alone.


Related Articles

  • Thiazide Diuretics: 50 Years and Beyond. Ernst, Michael E.; Grimm Jr., Richard H. // Current Hypertension Reviews;2008, Vol. 4 Issue 4, p256 

    Since the introduction of chlorothiazide into clinical practice in 1958, thiazide-type diuretics have weathered decades of criticism and controversy. Fifty years later, they remain the single most important class of antihypertensives available. Numerous clinical trials across broad populations...

  • Do Thiazide Diuretics Cause Diabetes? If So, Is It of Clinical Significance? Carter, Barry; Basile, Jan; Cushman, William; Sica, Domenic // Medical Roundtable: Cardiovascular Edition;Summer2010, Vol. 1 Issue 3, p152 

    The discussion focused primarily on: (1) the potential for new onset diabetes following initiation of thiazide diuretics, (2) the relationship of other drugs used in the treatment of hypertension, (3) review of clinical trial data, (4) review clinical practice guidelines, (5) the risks...

  • CLONIDINE & CHLORTHALIDONE.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p264 

    The article presents information on clonidine and chlorthalidone, antihypertensive and diuretic agents, including their dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • THE VASCULAR ACTIONS OF CLONIDINE IN MAN. Rodge, R. L.; Robinson, S. M. // Australian Journal of Experimental Biology & Medical Science;Apr1971, Vol. 49 Issue 2, p197 

    This article presents a study related to the vascular actions of clonidine in man. Clonidine has recently been introduced as a therapeutic agent for hypertension. The effect of the drug on arterial blood pressure depends on the dose, route and rate of administration and resting sympathetic tone....

  • CLONIDINE & CHLORTHALIDONE. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2009, p264 

    The article presents information on hypotensive agents clonidine and chlorthalidone, including dosage, usage, adverse reactions, side effects, precautions, and possible interaction with other drugs.

  • TRIBENZOR 20/5/12.5mg.  // Monthly Prescribing Reference;Sep2010, Vol. 26 Issue 9, pA8 

    The article offers information on the antihypertensive drug Tribenzor from Daiichi Sankyo. The drug combines antihypertensive agents in the angiotensin 2 receptor blocker (ARB), calcium channel blocker (CCB), and diuretic classes. The articlle discusses clinical trials of the drug, along with...

  • Improving Detection of Arrhythmia Drug-Drug Interactions in Pharmacovigilance Data through the Implementation of Similarity-Based Modeling. Vilar, Santiago; Lorberbaum, Tal; Hripcsak, George; Tatonetti, Nicholas P. // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Identification of Drug-Drug Interactions (DDIs) is a significant challenge during drug development and clinical practice. DDIs are responsible for many adverse drug effects (ADEs), decreasing patient quality of life and causing higher care expenses. DDIs are not systematically evaluated in...

  • Olmesartan medoxomil: enteropathy.  // WHO Drug Information;2013, Vol. 27 Issue 3, p220 

    The article reports on a 2013 drug safety communication from the U.S. Food and Drug Administration which warned consumers about a risk of enteropathy linked to the drug olmesartan medoxomil.

  • Antihypertensives.  // Cardiovascular Pharmacology Manual;2008, p11 

    The article presents information about several antihypertensives, they include mannitol, bumentanide and furosemide. Some of the diseases treated by these antihypertensives are hypertension and edema. Their adverse effects include hyponatremia, metabolic alkalosis, dehydration, dizziness and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics